此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Anxiety Reduction in TAVI Using Virtual Reality Trial (ART-VR)

2022年7月25日 更新者:Nicolas van Mieghem、Erasmus Medical Center
The ART-VR Trial is an international multi-center, open label, randomized controlled trial evaluating the effect of an immersive VR environment on procedural anxiety in patients undergoing transfemoral aortic valve replacement (TAVR) under local anaesthesia.

研究概览

详细说明

Virtual reality (VR) allows patients to be fully immerged in an engaging, interactive 3D environment. Its applications are broad and include treatment of phobias, stress-disorders, pain reduction. Recently, VR has been adopted in various medical procedures to reduce pre- and per-procedural anxiety. In TAVR, per-procedural VR immersion could potentially reduce patient anxiety leading to increased overall patient satisfaction. However, contemporary large scale, randomized evidence on VR application in TAVR is lacking.

The objective of this trial is to evaluate the effect of an immersive VR environment on procedural anxiety in patients undergoing TAVR under local anaesthesia in a randomized controlled setting. A total of 150 patients with severe aortic stenosis (AS) who undergo transfemoral TAVR under local aneasthesia will be included. The main study endpoint is procedural anxiety assessed on a visual analogue scale (VAS) directly post-procedure.

研究类型

介入性

注册 (预期的)

150

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Zuid Holland
      • Rotterdam、Zuid Holland、荷兰、3015 GD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age ≥ 18 years
  • Symptomatic severe aortic stenosis
  • Indication for transfemoral TAVI under local anaesthesia per local heart team consensus
  • Patient is able to understand and sign written informed consent
  • Patient speaks Dutch, German or English

Exclusion Criteria:

  • Need for emergent TAVI
  • Need for planned concomitant cardiac intervention during index procedure
  • History of TAVI under local anesthesia/conscious sedation
  • Chronic use of benzodiapines, opioids, pregabalin or antidepressants
  • History of opioid use (within 8-30 days prior to randomization)
  • Claustrophobia
  • Any psychiatric illness diagnosed by a psychiatrist or psychologist
  • Blindness or severe visual impairment despite visual aid (glasses, contact lenses)
  • Epilepsy
  • Extensive cognitive impairment (MMSE <21 or as diagnosed by geriatrician)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:VR-immersion
An immersive virtual reality experience will be generated by a head mounted device which shows the user pre-recorded videos (SynVR Relax & Distract, SyncVR Medical BV, Utrecht, The Netherlands). These videos are recorded in 360 degree views and matched with the users' viewing direction by the head mounted device matches. The user will not be able to see its in vivo surroundings (i.e. the Cathlab) and will be focused on the digital content. The VR immersion will be put into place throughout the entire TAVR procedure starting before femoral access obtainment and ending after access closure.
无干预:Non-VR control

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Procedural Anxiety
大体时间:Immediately after the TAVR procedure
Procedural anxiety assessed on a visual analogue scale directly post-procedure. Range: 0 (no anxiety) to 10 (worst anxiety).
Immediately after the TAVR procedure

次要结果测量

结果测量
措施说明
大体时间
Change of Anxiety
大体时间:1 day (From directly before the TAVR procedure until directly after the TAVR procedure)
Difference between pre-procedural and post-procedural anxiety visual analogue scale scores
1 day (From directly before the TAVR procedure until directly after the TAVR procedure)
Procedural Pain
大体时间:Immediately after the TAVR procedure
Procedural pain assessed on a visual analogue scale directly post-procedure. Range: 0 (no pain) to 10 (worst pain).
Immediately after the TAVR procedure
Procedural Use of Sedatives
大体时间:Up to 1 day (Depending on procedure duration)
Procedural sedative use and dosage. Amount of benzodiazepine used in milligrams
Up to 1 day (Depending on procedure duration)
Procedural Use of Analgesics
大体时间:Up to 1 day (Depending on procedure duration)
Procedural analgesic use and dosage. Amount of Lidocaine (or equivalent) used in milligrams
Up to 1 day (Depending on procedure duration)
Patient Procedural Satisfaction
大体时间:One day post procedure
Procedural satisfaction assessed after 24hrs using for procedures under regional anaesthesia. Score assessed on a visual analogue scale. Range: 0 (not at all satisfied) to 10 (very satisfied).
One day post procedure

其他结果措施

结果测量
措施说明
大体时间
Patient reported procedural Nausea and Vomiting
大体时间:Up to 1 day (Depending on procedure duration)
Patient reported nausea and vomiting during the procedure (yes/no)
Up to 1 day (Depending on procedure duration)
Admission time
大体时间:Up to 7 days
Time leaving cathlab until discharge
Up to 7 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年9月16日

初级完成 (预期的)

2022年12月31日

研究完成 (预期的)

2023年5月31日

研究注册日期

首次提交

2021年9月20日

首先提交符合 QC 标准的

2021年10月5日

首次发布 (实际的)

2021年10月6日

研究记录更新

最后更新发布 (实际的)

2022年7月27日

上次提交的符合 QC 标准的更新

2022年7月25日

最后验证

2022年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • MEC-2021-0417
  • NL77298.078.21 (其他标识符:Central Commissie Mensgebonden Onderzoek)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 共享支持信息类型

  • 研究方案

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅